相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。NPPB is a novel candidate biomarker expressed by cancer-associated fibroblasts in epithelial ovarian cancer
Kate Lawrenson et al.
INTERNATIONAL JOURNAL OF CANCER (2015)
Tumour T1 changes in vivo are highly predictive of response to chemotherapy and reflect the number of viable tumour cells - a preclinical MR study in mice
Claudia Weidensteiner et al.
BMC CANCER (2014)
Ultrasound Molecular Imaging in a Human CD276 Expression-Modulated Murine Ovarian Cancer Model
Amelie M. Lutz et al.
CLINICAL CANCER RESEARCH (2014)
Ovarian Cancer Cell Heparan Sulfate 6-O-Sulfotransferases Regulate an Angiogenic Program Induced by Heparin-binding Epidermal Growth Factor ( EGF)-like Growth Factor/EGF Receptor Signaling
Claire L. Cole et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2014)
IR TrueFISP with a golden-ratio-based radial readout: Fast quantification of T1, T2, and proton density
Philipp Ehses et al.
MAGNETIC RESONANCE IN MEDICINE (2013)
Effect of Indirect Nonequilibrium Atmospheric Pressure Plasma on Anti-Proliferative Activity against Chronic Chemo-Resistant Ovarian Cancer Cells In Vitro and In Vivo
Fumi Utsumi et al.
PLOS ONE (2013)
Evaluation of Clinically Translatable MR Imaging Biomarkers of Therapeutic Response in the TH-MYCN Transgenic Mouse Model of Neuroblastoma
Yann Jamin et al.
RADIOLOGY (2013)
Non-contrast T1-mapping detects acute myocardial edema with high diagnostic accuracy: a comparison to T2-weighted cardiovascular magnetic resonance
Vanessa M. Ferreira et al.
JOURNAL OF CARDIOVASCULAR MAGNETIC RESONANCE (2012)
Sharpening Wald-type inference in robust regression for small samples
Manuel Koller et al.
COMPUTATIONAL STATISTICS & DATA ANALYSIS (2011)
Estimation of Liver Function Using T1 Mapping on Gd-EOB-DTPA-Enhanced Magnetic Resonance Imaging
Takashi Katsube et al.
INVESTIGATIVE RADIOLOGY (2011)
Biomarkers of angiogenesis and their role in the development of VEGF inhibitors
N. Murukesh et al.
BRITISH JOURNAL OF CANCER (2010)
Quantified Tumor T1 Is a Generic Early-Response Imaging Biomarker for Chemotherapy Reflecting Cell Viability
Paul M. J. McSheehy et al.
CLINICAL CANCER RESEARCH (2010)
Phase III Study of Bevacizumab Plus Docetaxel Compared With Placebo Plus Docetaxel for the First-Line Treatment of Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer
David W. Miles et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Quantifying Antivascular Effects of Monoclonal Antibodies to Vascular Endothelial Growth Factor: Insights from Imaging
James P. B. O'Connor et al.
CLINICAL CANCER RESEARCH (2009)
Association of Computed Tomography Morphologic Criteria With Pathologic Response and Survival in Patients Treated With Bevacizumab for Colorectal Liver Metastases
Yun Shin Chun et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2009)
Dynamic MRI using iron oxide nanoparticles to assess early vascular effects of antiangiogenic versus corticosteroid treatment in a glioma model
Csanad G. Varallyay et al.
JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM (2009)
Phase III Trial of Cisplatin Plus Gemcitabine With Either Placebo or Bevacizumab As First-Line Therapy for Nonsquamous Non-Small-Cell Lung Cancer: AVAiL
Martin Reck et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Efficacy, Safety, and Biomarkers of Neoadjuvant Bevacizumab, Radiation Therapy, and Fluorouracil in Rectal Cancer: A Multidisciplinary Phase II Study
Christopher G. Willett et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Increased antitumor activity of bevacizumab in combination with hypoxia inducible factor-1 inhibition
Annamaria Rapisarda et al.
MOLECULAR CANCER THERAPEUTICS (2009)
Efficacy and safety of bevacizumab plus erlotinib for patients with recurrent ovarian, primary peritoneal, and fallopian tube cancer: A trial of the Chicago, PMH, and California Phase II consortia
Halla S. Nimeiri et al.
GYNECOLOGIC ONCOLOGY (2008)
Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer:: A randomized phase III study
Leonard B. Saltz et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma
Abby B. Siegel et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: A trial of the California, Chicago, and princess Margaret hospital phase II consortia
Agustin A. Garcia et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Standardized structural magnetic resonance imaging in multicentre studies using quantitative T1 and T2 imaging at 1.5 T
Sean C. L. Deoni et al.
NEUROIMAGE (2008)
Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer
Kathy Miller et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial
Bernard Escudier et al.
LANCET (2007)
Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: A Gynecologic oncology group study
Robert A. Burger et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer
Stephen A. Cannistra et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: Results from the Eastern Cooperative Oncology Group Study E3200
Bruce J. Giantonio et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Effect of vascular normalization, by antiangiogenic therapy on interstitial hypertension, peritumor edema, and lymphatic metastasis: Insights from a mathematical model
Rakesh K. Jain et al.
CANCER RESEARCH (2007)
Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer
Alan Sandler et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
High magnetic field water and metabolite proton T1 and T2 relaxation in rat brain in vivo
Robin A. de Graaf et al.
MAGNETIC RESONANCE IN MEDICINE (2006)
Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer
SB Wedam et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Exogenous gene expression in tumors: Noninvasive quantification with functional and anatomic imaging in a mouse model
D Yang et al.
RADIOLOGY (2005)
Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer
CG Willett et al.
NATURE MEDICINE (2004)
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer
H Hurwitz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU) leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer
F Kabbinavar et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
分享论文
